Affinivax

The novel 24-valent pneumococcal polysaccharide vaccine (PPSV) candidate from Affinivax and Astellas has notched U.S. FDA Breakthrough Therapy designation on the strength of new Phase 2 data, the companies announced Tuesday.

The results showed that ASP3772—based on Affinivax’s proprietary Multiple Antigen Presenting System (MAPS)—was well tolerated and induced antibody responses to each of its 24 serotypes, according to the press release. The study compared the shot to two market…

CARB-X committed up to $3.5 million to Affinivax to support the Massachusetts-based biotech’s development of a new vaccine to prevent Staphylococcus aureus infections, according to a CARB-X press release on Tuesday.

The Boston University-led nonprofit may add up to $18.5 million to the award if the vaccine—which will use the company’s Multiple Antigen Presenting System to include a variety of staphylococcal protein antigens—reaches certain milestones.

Affinivax announced last week that it has raised $226 million in Series C financing to advance its pipeline of MAPS (Multiple Antigen Presenting System) infectious disease vaccines—including its lead pneumococcal candidates and first-in-class shots targeting healthcare-acquired infections.

The Massachusetts-based company received an initial seed and Series A equity investment from the Gates Foundation in 2014 to launch its proprietary MAPS as a broad protection technology, and added…

The novel, 24-valent pneumococcal vaccine candidate from Affinivax proved safe, well-tolerated and highly immunogenic in Phase 1, according to data the Massachusetts-based company shared last week at the IDWeek infectious disease conference.

The study compared ASP3772—based on the biotech’s proprietary Multiple Antigen Presenting System (MAPS)—to Pfizer’s Prevnar 13 in adults ages 18-64. Affinivax has also completed enrollment in the Phase 2 portion of its study (in adults over 65),…

Merck released positive topline Phase 3 results this week showing that its 15-valent pneumococcal conjugate vaccine (PCV) candidate, V114, met its primary immunogenicity objectives in adults with HIV versus a Pfizer PCV13 control group.

In the press release, Merck also shared separate Phase 3 outcomes showing that V114 can be administered with the quadrivalent flu vaccine in healthy adults 50 or older. Merck is currently running 16 Phase 3 trials of V114 in different populations.

Three donor-funded companies touted successful investment offerings in recent weeks.

Affinivax announced last week that it has raised $120 million in Series B financing to advance its lead pneumococcal vaccine based on the company’s Multiple Antigen Presenting System (MAPS). The Massachusetts-based company received an initial seed and Series A equity investment from the Gates Foundation in 2014 to launch MAPS as a broad protection technology.

Meanwhile, Bugworks announced last…

Massachusetts-based Affinivax announced today that its novel pneumococcal vaccine ASP3772—based on its proprietary Multiple Antigen Presenting System (MAPS)—has entered Phase 1/2 trials.

In its press release, the company said that MAPS can present both the protein and the polysaccharide antigen to induce a more “broad and potent immune response.” In stage 1 of the study, the vaccine will go head-to-head against Pfizer’s 13-valent pneumococcal conjugate vaccine, Prevnar, in adults 18 to…

ClearPath Vaccines announced in December it will collaborate with Astellas Pharma to use Affinivax’s Multiple Antigen Presenting System (MAPS) to develop a vaccine to prevent Staphylococcus aureus infections.

Affinivax used seed funding from the Gates Foundation to start commercializing MAPS as a broad protection technology in 2014 for a pneumococcal vaccine under a licensing agreement from Boston Children’s Hospital.

Astellas is already a commercialization partner for Affinivax’…

Affinivax and Astellas announced this week that they are partnering to develop and commercialize a pneumococcal vaccine using Affinivax’s Multiple Antigen Presenting System (MAPS).

Astellas will lead and fully fund product development in return for worldwide commercial rights. Affinivax will receive an initial upfront payment of $10 million from Astellas and will be eligible to receive a range of development and commercial milestones and tiered royalties on future product sales, the…